



ELMMB Formulary Update

September 2018

Subscribe Now

And be one of the first to know...

BLACK traffic Light - not recommended for prescribing in primary or secondary care.

- **Omega 3 fatty acids** – removed from formulary in line with Prescribing for Clinical Need Policy
- **Ketamine oral** – use in chronic pain has limited clinical evidence & concerns over clinical risk, safety. (*Remains RED traffic light for use in hospice)
- **Ketamine infusion** – non-formulary

RED traffic light - Primary care prescribers should not be asked to prescribe (** denotes NHS England Commissioned)

- **Phytomenadione 10mg tablets** – included on formulary as an option for Vitamin K preparations.
- **Arsenic trioxide**** – acute promyelocytic leukaemia. Recommended as an option in line with [NICE TA526](#)
- **Pembrolizumab**** – untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable- recommended an option in line with [NICE TA522 \(Cancer Drugs Fund\)](#)
- **Brentuximab vedotin**** – CD30-positive Hodgkin lymphoma. Approved as an option in line with [NICE TA524](#)
- **Midostaurin**** - untreated acute myeloid leukaemia –recommended as an option in line with [NICE TA523](#)
- **Beta-interferons and glatiramer acetate**** - multiple sclerosis - recommended as an option in line with [NICE TA527](#)

AMBER Traffic Light - initiated by specialists but may then be passed to primary care for prescribing

- **Rivaroxaban 10mg (xarelto®)** – treatment of Deep vein thrombosis & Pulmonary Embolism and extended prevention of recurrent DVT & PE in adults
- **Donepezil, galantamine, rivastigmine and memantine** – for the treatment of Alzheimers' disease – updated as per [NICE TA217](#)
- **Methylphenidate prolonged release (Xaggitin XL®)** –alternative to Concerta- [AMBER SHARED CARE](#)
- **Memantine orodispersible tablets** – 3rd line option, only if swallowing difficulties

GREEN Traffic Light - may be prescribed by all prescribers within local or national recommendations

- **Betnesol N® ear drops** - (Gentisone® HC ear drops removed from formulary)

Guidelines

- [ELHT: T34 Ambulatory Syringe Pump Policy](#) - updated
- [Pennine Lancashire Research Strategy](#)
- [Research and Development Policy](#)
- **ELHT: Peri Procedural management of patients on anticoagulants, antiplatelets & Low molecular weight heparin** – updated policy.
- **ELHT: Oral anticoagulation Guidelines** – update
- **Proton Pump Inhibitors – Patient information leaflet** – acknowledged by ELMMB
- [ELHE: Care Home Audit Resources](#) – available on ELMMB Care Home Resource

Other

- [Medicines Management Board Minutes](#)
- [Prescribing Hot Topics](#)
- [Shared Care Guidelines](#)
- [Drug Safety Updates](#)
- [Adult Social Care Training Programme 2018](#)
- [Patient Group Directions](#)
- [Nice Bites](#)
- [Training for Care Home Staff](#)
- [E-learning hub](#)
- [Continence and Catheter Formulary](#)